Christine Helou, NP
Family · Fairfax, VANPI 1528318334
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 80.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $20,696 and has fallen 84.7% since, to $3,170 in 2025. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $384.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$23K
- Johnson & Johnson$4K
- Fresenius Kabi USA, LLC$560
- Chiesi USA, Inc.$300
- Bristol Myers Squibb$160
- AbbVie$157
- plus $802 from 18 others
What the payments were for
- Consulting fees$3,38512%
- Speaking & faculty fees$13,15047%
- Travel & lodging$10,36837%
- Food & beverage$1,1164%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $22,568 |
| Johnson & Johnson | 5 | $3,552 |
| Fresenius Kabi USA, LLC | 1 | $560 |
| Chiesi USA, Inc. | 1 | $300 |
| Bristol Myers Squibb | 6 | $160 |
| AbbVie | 5 | $157 |
| Novartis | 6 | $147 |
| Lilly USA, LLC | 2 | $105 |
| Daiichi Sankyo Inc. | 4 | $85 |
| Beigene USA, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Mirati Therapeutics, Inc. | 2 | $63 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $35 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Incyte Corporation | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Gilead | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,099 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 14 | $176,524 |
| IbrancePalbociclib | 11 | $163,063 |
| PromactaEltrombopag Olamine | 11 | $77,546 |
| XareltoRivaroxaban | 18 | $18,942 |
| EliquisApixaban | 11 | $6,568 |
| Acyclovir | 88 | $1,536 |
| Dexamethasone | 54 | $724 |
| Anastrozole | 12 | $529 |
| Hydroxyurea | 14 | $317 |
| Gabapentin | 26 | $234 |
| Ondansetron Hcl | 13 | $160 |
| Oxycodone Hcl | 13 | $156 |
| Warfarin Sodium | 11 | $108 |
| Trazodone Hcl | 12 | $103 |
| Levofloxacin | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $66 | $176,52414 claims |
| PfizerIbrance, Eliquis | $22,568 | $169,63122 claims |
| NovartisPromacta | $147 | $77,54611 claims |
| Johnson & JohnsonXarelto | $3,552 | $18,94218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Fairfax
- Meagan AdamsonFairfax$34K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.